These findings provide evidence for why targeting inflammation outside the lungs [against covid] has been disappointing so far. Instead, a more targeted approach that inhibits the expression and activation of complement proteins in lung cells could yield better results. For example, the researchers found that pairing Remdesivir with Ruxolitinib inhibited the complement response much more effectively than a monotherapy of the drugs independently, using an in vitro model of alveolar cells.
The “Unexpected” Reason Why COVID Antivirals Don’t Work
This may be why inhalers containing budesonide greatly lower covid symptoms: Over-the-counter asthma inhalers show 90% reduction of covid symptoms.
American Buddhist Net 